KINDSTAR GLOBAL (09960) released its interim results, reporting revenue of 474 million yuan, an increase of 3.7% year-on-year. The oncology testing segment achieved significant growth.

KINDSTAR GLOBAL (09960) announced its performance for the six months ending June 30, 2026, during which the group achieved revenue of 474 million yuan, an increase of 3.7% year-on-year; gross profit was 218 million yuan, an increase of 10.9% year-on-year; the loss attributable to the owners of the parent was 18.864 million yuan; basic loss per share was 1.89 cents. The announcement stated that the revenue growth was mainly attributed to the stable performance of the core segment and the rapid expansion of the oncology testing sector. In particular, the oncology testing sector benefited from deep synergies in channels, technology, and customer resources between the acquisition targets and existing businesses, achieving significant incremental growth and becoming a new growth engine for the group. Hematology testing, as a core segment, continued to play a stabilizing role and maintained stability. The increase in gross margin was primarily due to revenue growth, the release of synergies from acquisitions, and the group's ongoing optimization of organizational structure and human resource allocation. Strict cost control measures had a positive effect, with employee costs and other operating costs decreasing by approximately 5.7% and 7.9% year-on-year, respectively. The increase in raw materials was commensurate with the expansion of business scale, leading to a continuous optimization of the overall cost structure and a steady enhancement of profitability. In the first half of 2026, under the macro environment of normalized compliance in the medical industry and the deep release of demand for precise diagnosis and treatment, KINDSTAR GLOBAL demonstrated strong business resilience and clear strategic focus. In the face of deep structural changes in the industry, the group leveraged the synergistic advantages of multiple technology platforms and a nationwide specialized service network to continuously solidify its operational foundation. Hematology testing, as a traditional area of strength, continued to play a "stabilizing stone" role, consolidating the market's foundation; at the same time, the "big oncology" strategic sector, meticulously crafted by the group with a forward-looking perspective, reached a pivotal turning point. The full cycle of diagnosis has gradually taken shape, encompassing early screening, precise diagnosis and typing, companion diagnostics, and recurrence monitoring, with the synergistic effects of the non-hematology specialty matrix becoming increasingly apparent. In the first half of 2026, the overall business revenue of the sector once again achieved rapid growth, reaching 46%. Through a business layout that balances offense and defense, the group effectively mitigated risks from policy and market volatility, achieving a steady upgrade of its business structure toward high added value, compliance, and a dual-driven model of reagents and services.